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ABSTRACT 
Objective 5 
The aim of the study is to determine the effect of lutein combined with vitamin and mineral 
supplementation on contrast sensitivity in people with age-related macular disease. 
 
Design 
A prospective, nine-month, double-masked randomised controlled trial.  10 
 
Setting 
Aston University, Birmingham, UK and a UK optometric clinical practice. 
 
Subjects 15 
ARM and atrophic AMD participants were randomised (using a random number generator) to either 
placebo (n = 10) or active (n = 15) groups. Three of the placebo group and two of the active group 
dropped out.  
 
Interventions 20 
The active group supplemented daily with 6 mg lutein combined with vitamins and minerals. The outcome 
measure was contrast sensitivity (CS) measured using the Pelli-Robson chart, for which the study had 80 
% power at the 5 % significance level to detect a change of 0.3 log units.  
 
Results 25 
The CS score increased by 0.07 ± 0.07 and decreased by 0.02 ± 0.18 log units for the placebo and active 
groups respectively. The difference between these values is not statistically significant (z = -0.903, p = 
0.376). 
 
 30 
 
 3 
 
Conclusion 
The results suggest that 6 mg of lutein supplementation in combination with other antioxidants is not 
beneficial for this group. Further work is required to establish optimum dosage levels. 35 
 
 Sponsorship 
The project was sponsored by the UK College of Optometrists. Intervention and placebo tablets were 
provided by Quest Vitamins Ltd UK. 
 40 
Descriptors 
Age-related macular disease, lutein, randomised controlled trial, nutrition, antioxidants. 
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INTRODUCTION 60 
There is interest in the use of nutrition as a prevention and treatment strategy for age-related macular 
disease (ARMD) as it is the leading cause of visual disability in the developed World (Klein et al., 1997), 
and because treatment options are currently lacking (Zarbin, 2004). According to an international 
classification and grading system (Bird et al., 1995), this condition can be divided into early (age-related 
maculopathy, ARM) and late (age-related macular degeneration, AMD) stages.  65 
 
Interest has been raised into the protective role of the oxygenated xanthophylls group of carotenoids in 
the eye, particularly the retina. Lutein, zeaxanthin and its isomer meso-zeaxanthin, are the only 
carotenoids present in the lens [1] and retina [2] and are also known as macular pigment (MP). It has 
been suggested that they play a similar role in humans as in plants, as antioxidants and screeners of high-70 
energy blue light [3].   
 
The absorbance spectrum of MP peaks at 460 nm and it is purported to act as a broadband filter, reducing 
the sensitivity of the macular region to short wavelength light which is most damaging in the 440 to 460 
nm range (Pease et al., 1987, Reading and Weale, 1974). Zeaxanthin is reported to be a superior 75 
photoprotector during prolonged light exposure; the shorter time-scale of protective efficacy of lutein has 
been attributed to oxidative damage of the carotenoid itself (Sujak et al., 1999).  
 
The MP also acts as a scavenger of reactive oxygen species (ROS). The relatively high concentration of 
MP in the inner retinal layers (Snodderly et al., 1984) is very likely to indicate a photoprotective role, while 80 
the presence of MP in the rod outer segments (Sommerburg et al., 1999), is suggestive of a ROS-
quenching function. Lutein and zeaxanthin have been found in higher concentration in the rod outer 
segments of the perifoveal retina than the peripheral retina, again lending support to their proposed 
protective role in ARM and AMD (Rapp et al., 2000). 
 85 
This RCT was designed to investigate the effect of 6 mg lutein combined with 750 μg retinol equivalents, 
250 mg vitamin C, 34 mg vitamin E, 10 mg zinc, and 0.5 mg copper on contrast sensitivity measured 
 5 
using the Pelli-Robson chart (Clement Clarke International, Edinburgh Way, Harlow, Essex, CM20 2TT, 
UK) in ARM affected eyes. Contrast sensitivity (CS) is a particularly relevant outcome measure for those 
with ocular disease as it provides a measure of real-world visual function (Hyvarinen, 1995).  CS may help 90 
to provide a more complete assessment of visual function in macular disease, and it has been suggested 
that the test may be a superior predictor of daily living activities and mobility than visual acuity (VA) alone 
(Jin et al., 1992, Mones and Rubin, 2005). CS is reported to be a better measure of the ability to judge 
distances (Rubin et al., 1994) and discriminate between objects (Scott et al., 2002) and has also been 
reported to detect vision loss due to AMD prior to VA testing (Hyvarinen et al., 1983). Although there is a 95 
moderate correlation between VA and CS (Rubin, Roche, Prasada-Rao and Fried, 1994, Rubin et al., 
1997), these two measures are not interchangeable (Haegerstrom-Portnoy et al., 2000). The effect, 
however, of a six letter loss of CS has been reported to have a similar impact on self-reported visual 
disability as a 15 letter loss of VA (Rubin et al., 2001). The inclusion of CS in visual assessment of 
macular disease patient may be useful in monitoring disease progression, evaluating the benefit of 100 
treatment, and designing appropriate rehabilitation strategies (Fletcher and Schuchard, 2006). 
 
During the design of the trial, 6 mg daily intake of lutein had been reported to be associated with a 
reduced risk of AMD (57 % lower risk for the highest quintile of lutein intake, 6 mg per day, relative to the 
lowest quintile, 0.5 mg per day) (Seddon et al., 1994). The reasons for using a multi-ingredient formulation 105 
include the fact that ARM has a multifactorial aetiology, and so may be affected by more than one nutrient, 
and also that nutrients are thought to work synergistically together. A relevant example of this synergism 
is the facilitation of vitamin A transport from the liver by zinc (Newsome et al., 1994). A review of the 
nutrients considered suitable for inclusion in an ocular nutritional supplement has been published (Bartlett 
and Eperjesi, 2004). 110 
 
Methods 
Protocol 
The study was approved by the Aston University Human Sciences Ethical Committee (code 02/M). The 
tenets of the Declaration of Helsinki were followed (World Medical Association, 1997). The trial was 115 
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registered for an International Standard Randomised Controlled Trial Number (ISRCTN 78467674), and 
the method has been published (Bartlett and Eperjesi, 2003). Reporting of this RCT adheres to the 
guidelines set out in the revised CONSORT statement (Moher et al., 2001). 
 
Recruitment 120 
Recruitment methods employed included sending study information to local optometrists, 
ophthalmologists, and a specialist centre for rehabilitation of people with sight loss. Enrolment was carried 
out by HB, who, along with FE, was masked to group assignment. 
 
The main research centre was Aston University, Birmingham. A secondary research centre was a UK 125 
optometric clinical practice. 
 
Inclusion/exclusion criteria 
For inclusion participants had to 1) provide written informed consent, 2) be available to attend one of the 
research centres, 3) present with no ocular pathology in at least one eye, or no ocular pathology other 130 
than ARM, identified using the International Classification and Grading System for Age-Related 
Maculopathy and Age-Related Macular Degeneration (Bird, Bressler, Bressler, Chisholm, Coscas, Davis, 
Dejong, Klaver, Klein, Klein, Mitchell, Sarks, Sarks, Sourbane, Taylor and Vingerling, 1995). This 
definition of ARM includes soft or hard drusen, and areas of increased or decreased pigment associated 
with these drusen. Fundus examination was used to determine the presence of ARM. Exclusion criteria 135 
included type I and II diabetes, prescribed anti-platelet or anti-coagulant medication because of possible 
interaction with vitamin E (The ATBC Cancer Prevention Study Group, 1994), and concurrent use of 
nutritional supplements that potentially raised vitamin and mineral intake above the recommended safe 
limits (Bartlett and Eperjesi, 2005). Those with AMD in one or both eyes were excluded.  
 140 
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Randomisation 
Only one investigator (HB) was involved in the randomisation process, which employed the random 145 
number generator in Microsoft Excel for Windows XP. Odd and even numbers were used to identify 
group. 
 
Outcome measure 
Contrast sensitivity (CS) was measured using a Pelli-Robson chart (Clement Clarke International, 150 
Edinburgh Way, Harlow, Essex, CM20 2TT, UK), and scored per letter. 
 
Masking 
The study formulation and placebo tablets were produced by Quest Vitamins Ltd, and were identical in 
external and internal appearance, and taste. The manufacturer allocated distinguishing symbols, μ and λ 155 
to the outer packaging, which was otherwise identical.  The code for the symbols was withheld by the 
manufacturer until all data had been collected and analysed. Throughout this report, the letters P and A 
will be used to refer to the placebo and active formulation respectively.  
 
The study formulation contained the following: 160 
Lutein esters   6mg 
Retinol    750μg 
Vitamin C   250mg 
Vitamin E   34mg 
Zinc    10mg 165 
Copper    0.5mg 
The placebo tablets contained cellulose. 
 
Participants in both groups were instructed to take one tablet, at the same time every day, with food. They 
were encouraged not to alter their diets, or to change their current supplementation regime.  170 
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Follow up  
Data collection took place at baseline and nine months and was carried out by HB. Data were collected 
between March 2003 and December 2004.  
 175 
Statistical analysis 
The change between baseline and nine month values was calculated. SPSS software (version 11) for 
Microsoft Windows XP was used for analysis. The non-parametric Mann-Whitney U test was used to 
determine whether the means of these values differed at the 5% significance level between the two 
groups.  180 
 
Sample size calculation 
A group size of nine was calculated to be sufficient to provide 80 % power at the 5 % significance level for 
CS based on an effect size of 0.3 log units and mean and standard deviation values taken from a sample 
of  50 ARM and atrophic AMD patients of the University optometry clinic (1.39 ± 0.22 log CS). 185 
 
Participant flow 
Out of the 36 people that completed enrolment questionnaires, six did not meet the inclusion criteria or 
decided not to enrol. The remaining 30 individuals were randomised into the treatment or placebo group; a 
breakdown is shown in table 1. 190 
 
Insert table 1 about here. 
 
Statistical analysis was carried out on a per protocol basis. Compliance was assessed by counting 
remaining tablets at the follow-up visits, and averaged 94.4 %. There was no significant difference in 195 
compliance between groups. 
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Baseline characteristics 200 
Although it is not correct to test for differences between two randomly allocated groups using conventional 
statistical tests as any differences will have arisen by chance alone, we acknowledge that the small 
sample size means that there could be differences between the groups. For this reason we have reported 
this information. The cohort ranged in age from 55 to 82 years (mean ± SD: 69.2 ± 7.8) and 53 % were 
female. There was no significant difference in age or gender between groups. There was no significant 205 
difference in baseline visual acuity (VA) between active (0.20 ± 0.28) and placebo (0.08 ± 0.15) groups (t 
= - 1.229, p = 0.229). All participants were White British. There was no significant difference in iris colour 
between groups. The baseline CS scores were 1.43 ± 0.20 and 1.36 ± 0.20 log units for the placebo and 
active groups respectively. Both groups fell below the normal CS score reported for this age group, which 
is 1.65 log units and is repeatable to within ± 0.15 log units (Elliott et al., 1990).  210 
 
There was no significant difference between groups for age, smoking history (pack years) and years spent 
living abroad. Dietary intake of lutein, vitamins C and E, retinol equivalents, and zinc was assessed using 
food diaries and food frequency questionnaires. Analysis of food diaries was carried out using FoodBase 
2000 (The Institute of Brain Chemistry and Human Nutrition, 166-220 Holloway Road, London N7 8DB, 215 
UK) for Microsoft Windows XP. There was no difference between groups except that the P group 
consumed significantly more vitamin C (161.1 ± 71.0) than the A group (88.0 ± 53.7: t = 3.04, p = 0.005). 
There was no difference in nutritional supplementation habits between P and A groups. 
 
Adverse effects  220 
There were no reported adverse effects from any of the study participants. 
 
RESULTS 
Masking success 
End of trial assessment using questionnaires indicated masking success. Out of those participants taking 225 
the placebo tablet, 10 % correctly guessed which tablet they were taking, and 10 % incorrectly guessed. 
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Out of those taking nutritional supplement, 13 % guessed correctly which tablet they were taking, and 7 % 
incorrectly guessed. The remaining participants did not know which group they were randomised to. 
 
Assessment of change in baseline characteristics 230 
All participants were asked to fill out end-of-trial food diaries and food frequency questionnaires in order to 
assess any change in dietary habits over the trial period. Eighty percent of the end-of-trial food frequency 
questionnaires and food diaries were returned by the P group and 90 % by the A group.  
 
There was no change in dietary lutein, vitamin C, vitamin, E, or retinol for any of the groups. However, 235 
there was a significant change in mean zinc intake from 9.17 ± 2.44 mg to 11.41 ± 3.64 mg (t = - 2.912, df 
= 19, p = 0.04) in the A group. There was no change in ocular health in either group.  
 
Main outcome 
The mean CS score increased by 0.07 ± 0.07 log units in the P group and decreased by 0.02 ± 0.18 log 240 
units in the A group. A Mann-Whitney test was used to compare groups because the P group data set was 
not normally distributed (Kolmogorov-Smirnov = 0.320, p = 0.004). There was no significant difference 
between the P and A group in the change in CS over nine months (z = -0.903, p = 0.366). There was an 
improvement in CS over nine months in the P group (p = 0.03, eta squared = 0.21), although this is not 
clinically significant (Elliott, Sanderson and Conkey, 1990). 245 
 
DISCUSSION 
The results suggest that supplementing for nine months with a formulation containing 6 mg lutein, 750 μg 
retinol equivalents, 250 mg vitamin C, 34 mg vitamin E, 10 mg zinc, and 0.5 mg copper does not have an 
effect on CS in ARM-affected eyes. This is the only RCT to investigate the effect of nutritional 250 
supplementation on visual function in people with ARM. 
 
Other RCTs have looked at the effect of nutritional supplementation on ARM and AMD. The Age-related 
Eye Disease Study (AREDS) found that a formulation containing 500 mg vitamin C, 273 mg vitamin E, 15 
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mg beta-carotene, and 80 mg zinc was moderately effective in preventing progression to advanced AMD. 255 
This effect was only seen in those subjects with extreme intermediate drusen, large drusen or non-central 
geographic atrophy without advanced AMD (The AREDS Research Group, 2001). The Lutein and 
Antioxidant Supplement Trial (LAST) was a 12-month RCT designed to evaluate the effect of 10 mg lutein 
alone or 10 mg lutein combined with additional carotenoids and antioxidants/minerals on MP optical 
density and objective visual outcome measures in 90 subjects with AMD. Glare recovery and contrast 260 
sensitivity significantly improved with both interventions, although it is worth noting that the study 
population was 95.6 % male (Richer et al., 2004). 
 
Although no positive effect of supplementation was shown in this case, the study did have 80 % power at 
the 5 % significance level to detect a change of 0.3 log units. This effect size was selected because the 265 
measurement of CS using the Pelli-Robson chart has been shown to be reliable to ± 0.15 log units, which 
means that a change of 0.3 log units can be classed as clinically significant. A change of this size would 
also have brought both placebo and active groups into the normal range (1.50 to 1.80 log units) (Elliott, 
Sanderson and Conkey, 1990) for their age. 
 270 
Research into the role of xanthophylls for retinal health is ongoing. There is evidence for selective 
deposition of lutein in the retina (Bernstein et al., 2001, Rapp, Maple and Choi, 2000), increase of retinal 
and serum levels of lutein with supplementation (Berendschot et al., 2000, Hammond et al., 1997, 
Landrum et al., 1997), and an increased risk of ARMD with low serum (EDCCS Group, 1993) and retinal 
(Beatty et al., 2001, Bone et al., 2001) lutein levels. Lutein/zeaxanthin supplementation has been linked 275 
with improved visual function in patients with congenital retinal degenerations (Dagnelie et al., 2000) and 
with AMD (Richer, 1999). 
 
The lack of positive effect shown by this RCT may be explained by the selected lutein dosage level. When 
the study was designed, the recommended daily intake of lutein was 6 mg, based on an epidemiological 280 
study that determined a 57 % reduced risk for AMD in those consuming 6 mg lutein/zeaxanthin per day 
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compared to those consuming 0.5 mg per day) (Seddon, Ajani, Sperduto, Hiller, Blair, Burton, Farber, 
Gragoudas, Haller and Miller et, 1994). 
 
More recent work has demonstrated a general increase in macular pigment optical density (MPOD - 285 
retinal levels of lutein/zeaxanthin) response with dose (Chew et al., 2003, Landrum et al., 2004). In one 
study, those supplementing with 10 mg or 20 mg of lutein, but not 5 mg lutein, for 120 days had an 
increased response compared with those taking a placebo (Landrum, Bone, Dixon, Etienne-Levielle, 
Formosa and Saint-Louis, 2004). Another study showed that, in patients with varying stages of ARM and 
AMD, doses of 2.5 mg, 5 mg, and 10 mg lutein all induced an increase in serum levels by one month, and 290 
a peak by three months. Three-month levels ranged from 104 % to 339 % change from baseline. Macular 
pigment optical density levels, however, remained largely unchanged over the six-month supplementation 
period. In other studies the retinal response has been reported to occur after 15 weeks with increased 
dietary levels of corn and spinach (Hammond, Johnson, Russell, Krinsky, Yeum, Edwards and Snodderly, 
1997), 140 days with 30g/d supplemental lutein or zeaxanthin, and six months with 2.4g/d supplemental 295 
lutein or zeaxanthin (Landrum, Bone, Joa, Kilburn, Moore and Sprague, 1997). The response rates 
appear to be variable, and this may explain why we did not find an effect on CS. Our dosage of 6 mg per 
day lutein may not have increased MPOD. 
  
A putative lutein-binding protein has been found in the retinae of human eyes (Yemelyanov et al., 2001), 300 
which binds with high affinity and specificity to lutein and other xanthophylls. It has been suggested that 
people who are less responsive to xanthophyll supplementation may be so because of genetic differences 
that result in reduced or less efficient binding proteins (Landrum and Bone, 2004). This factor may have 
had an effect on the outcome of this trial. The protein may also act as an enzyme for the conversion of 
lutein to meso-zeaxanthin, which predominates over lutein and zeaxanthin at the fovea. There is no 305 
current evidence to support the suggestion that people with ARM or AMD have a reduced ability to absorb 
lutein or zeaxanthin at the macula.  
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The formulation also contained lutein esters extracted from marigold flowers, rather than pure lutein. It 
could be argued that this affected the results of this study. In flower petals, the pigments are stored as 310 
diesters, whereas they are found unesterified in most fruits and vegetables (Goodwin, 1980). In fact, 
industrial research showed that 93 % of the lutein and zeaxanthin found in fruits, vegetables, and eggs is 
found as lutein, rather than lutein esters (DeFreitas, 2004). Lutein esters contain two fatty acid groups that 
must be cleaved off before the body can use the lutein (Noy, 2000). The efficacy of this hydrolysis of lutein 
esters into lutein occurs with an efficacy that is well below 5 % (Breithaupt et al., 2002, Granado et al., 315 
2002). Furthermore, a negative correlation between age and serum lutein levels in individuals consuming 
lutein esters has been reported that was not found in people supplementing with lutein (Chung et al., 
2004). This may suggest that the ability to hydrolise lutein esters declines with age.   
 
These factors have been used to support the argument that lutein esters are less bioavailable than pure 320 
lutein. Studies carried out to investigate differences in bioavailability between pure and esterified lutein do 
not support this hypothesis. One study reported no significant difference in serum lutein response 
between 6 mg lutein from spinach, 6 mg pure lutein, and 10.23 mg lutein esters (Chung, Rasmussen and 
Johnson, 2004).  In another study, serum response was greater from lutein esters than pure lutein (Bowen 
et al., 2002). Although these studies suggest that the use of lutein esters in our formulation should not 325 
have hindered bioavailability, it is important to note that they recorded serum response rather than retinal 
response. Although the retinal response is related to serum response, and dietary modification affects 
both, the retinal response is reported to be slower than the serum response.  
 
Although serum antioxidant checks were considered during the design of the trial, this evidence 330 
suggested that it would only provide a short-term indication of blood antioxidant levels and so would not 
provide any additionally useful information about compliance. The inclusion of blood testing in the protocol 
may also have hindered recruitment. 
 
All participants were White British, and so the results cannot be applied to other ethnic groups. 335 
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It is difficult to explain the counterintuitive improvement in mean CS score over the trial period within the P 
group, although this change was not clinically significant. The trial results could have been confounded by 
the fact that the P group consumed almost twice as much vitamin C than the A group. The increase in 
dietary intake of zinc in the A group is also worth mentioning, although it could be argued that, if anything, 340 
this change would increase rather than decrease the likelihood of finding a treatment effect based on the 
results of trials such as AREDS (The AREDS Research Group, 2001). 
 
The mixed antioxidant and mineral formulation does not permit investigation of the effect of specific 
nutrients on visual function. The rationale for using a mixed formulation is that nutrients are thought to 
work synergistically together. A relevant example of this synergism is the facilitation of vitamin A transport 
from the liver by zinc (Newsome, Miceli, Liles, Tate and Oliver, 1994).
 
 
Although this study investigated the effect of nutritional supplementation in eyes affected by ARM, there is 
also interest in lutein supplementation for healthy eyes. It has been hypothesised that the blue-light filter 
effect of lutein/zeaxanthin may reduce longitudinal chromatic aberration (Wald, 1945)
 
The acuity 
hypothesis states that retinal lutein may improve visual acuity for images that are illuminated by white light 
by absorbing poorly focussed short wavelengths before this light is processed by the retina (Hammond et 
al., 2001). The findings of a study by the authors that investigated the effect of lutein and antioxidant 
supplementation on visual function in healthy eyes has yet to be published. Despite a lack of empirical 
evidence, lutein/zeaxanthin supplements are being taken by the public in an attempt to improve retinal 
health and vision in the absence of disease (Mares-Perlman, 1999). We are not aware of any currently 
published trials that have investigated this hypothesis. 
 345 
The finding of no evidence of effect of nine months of nutritional supplementation on CS adds to the 
literature, and may suggest that daily intake of 6 mg lutein or less does not have a beneficial effect on 
ARM. Further clinical trials are required to investigate optimum lutein dosage levels, and we await the 
results of a large multi-centred RCT. 
 350 
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